Baidu
map
EUR THYROID J 润色咨询

European Thyroid Journal

出版年份：暂无数据 年文章数：416 投稿命中率： 开通期刊会员，数据随心看

出版周期：暂无数据 自引率：暂无数据 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2182185, encodeId=f4102182185d6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：有人投过这个杂志吗？审稿过程包含哪些阶段呀？我投出去20天，状态如下，请问PS: Not Assigned是什么意思？是还没有分配编辑，还是已经开始审稿了？<br>2023.12.29， submit manuscript<br>2024.01.17 <br>ADM: Office, Editorial<br>PS: Not Assigned<br>Under Review<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Wed Jan 17 13:51:23 CST 2024, time=2024-01-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2207781, encodeId=89b3220e78166, content=甲减方向，投稿立刻under review。ADM和PS均未分配, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4306577087, createdName=兰大小杨, createdTime=Sat Jun 01 15:49:58 CST 2024, time=2024-06-01, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1110757, encodeId=4f691110e576f, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1110758, encodeId=a4701110e586f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:54 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2024-01-17 ms2000000984739514 来自浙江省

    审稿速度:2.0 | 投稿命中率:50.0
    经验分享：有人投过这个杂志吗？审稿过程包含哪些阶段呀？我投出去20天，状态如下，请问PS: Not Assigned是什么意思？是还没有分配编辑，还是已经开始审稿了？
    2023.12.29， submit manuscript
    2024.01.17
    ADM: Office, Editorial
    PS: Not Assigned
    Under Review

    4

    展开4条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2182185, encodeId=f4102182185d6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：有人投过这个杂志吗？审稿过程包含哪些阶段呀？我投出去20天，状态如下，请问PS: Not Assigned是什么意思？是还没有分配编辑，还是已经开始审稿了？<br>2023.12.29， submit manuscript<br>2024.01.17 <br>ADM: Office, Editorial<br>PS: Not Assigned<br>Under Review<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Wed Jan 17 13:51:23 CST 2024, time=2024-01-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2207781, encodeId=89b3220e78166, content=甲减方向，投稿立刻under review。ADM和PS均未分配, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4306577087, createdName=兰大小杨, createdTime=Sat Jun 01 15:49:58 CST 2024, time=2024-06-01, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1110757, encodeId=4f691110e576f, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1110758, encodeId=a4701110e586f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:54 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2024-06-01 兰大小杨 来自甘肃省

    甲减方向，投稿立刻under review。ADM和PS均未分配

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2182185, encodeId=f4102182185d6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：有人投过这个杂志吗？审稿过程包含哪些阶段呀？我投出去20天，状态如下，请问PS: Not Assigned是什么意思？是还没有分配编辑，还是已经开始审稿了？<br>2023.12.29， submit manuscript<br>2024.01.17 <br>ADM: Office, Editorial<br>PS: Not Assigned<br>Under Review<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Wed Jan 17 13:51:23 CST 2024, time=2024-01-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2207781, encodeId=89b3220e78166, content=甲减方向，投稿立刻under review。ADM和PS均未分配, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4306577087, createdName=兰大小杨, createdTime=Sat Jun 01 15:49:58 CST 2024, time=2024-06-01, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1110757, encodeId=4f691110e576f, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1110758, encodeId=a4701110e586f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:54 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2021-12-29 ms6000000264964247

    上传文章有什么要求？

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2182185, encodeId=f4102182185d6, content=审稿速度:2.0 | 投稿命中率:50.0<br>经验分享：有人投过这个杂志吗？审稿过程包含哪些阶段呀？我投出去20天，状态如下，请问PS: Not Assigned是什么意思？是还没有分配编辑，还是已经开始审稿了？<br>2023.12.29， submit manuscript<br>2024.01.17 <br>ADM: Office, Editorial<br>PS: Not Assigned<br>Under Review<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=db655482134, createdName=ms2000000984739514, createdTime=Wed Jan 17 13:51:23 CST 2024, time=2024-01-17, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2207781, encodeId=89b3220e78166, content=甲减方向，投稿立刻under review。ADM和PS均未分配, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4306577087, createdName=兰大小杨, createdTime=Sat Jun 01 15:49:58 CST 2024, time=2024-06-01, status=1, ipAttribution=甘肃省), GetPortalCommentsPageByObjectIdResponse(id=1110757, encodeId=4f691110e576f, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:54 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1110758, encodeId=a4701110e586f, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71734776539, createdName=MS54455111222, createdTime=Mon Dec 27 14:52:54 CST 2021, time=2021-12-27, status=1, ipAttribution=)]
    2021-12-27 MS54455111222

    如何判断两种药物之间是协同作用还是相加作用？

    1

    展开1条回复
共12条页码: 1/2页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map